Mass meeting

Vizgen Kicks Off AGBT with Enhanced MERFISH Chemistry Updates and 2024 Product Roadmap Highlights

Retrieved on: 
Monday, February 5, 2024

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.
  • In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.
  • The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research.
  • Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024.

Vizgen and Scale Biosciences Unveil Strategic Partnership at AGBT

Retrieved on: 
Monday, February 5, 2024

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.
  • As part of the strategic partnership, Vizgen and ScaleBio will leverage their respective technology to generate high resolution data from serial mouse brain tissue sections for single cell RNA-seq, single cell DNA methylation and targeted spatial gene expression.
  • Such data can then be leveraged for a variety of applications, including neuroscience and cancer biology,” said Terry Lo, President and CEO of Vizgen.
  • In addition, Vizgen will sponsor a Women’s Networking Event on Tuesday, February 6, from 5:15 – 7:15 p.m.

Ultima Genomics to Launch UG 100™ System and Present Data at AGBT

Retrieved on: 
Monday, February 5, 2024

Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.

Key Points: 
  • Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.
  • The Gold Sponsor workshop will also include presentations by customers and collaborators from multiple leading institutions including:
    Stacey Gabriel, Ph.D., Executive Vice President of Platforms and Scientific Execution, Institute Scientist, Broad Institute of MIT and Harvard
    Aziz Al’Khafaji, Ph.D., Associate Director, Technology Development – Genomics Platform, Broad Institute of MIT and Harvard
    Will Salerno, Ph.D., Executive Director of Genome Informatics & Data Engineering, Regeneron Pharmaceuticals
    Dan Landau, M.D., Ph.D., Professor of Physiology and Biophysics, Weill Cornell Medical College
    Join Ultima for a series of talks and poster sessions, including:
    Ultima Genomics will be hosting the Gold Sponsor Workshop and Lunch entitled “Genomics unleashed: the $100 genome and beyond” at 12:00 pm in Grand Sierra Ballroom D&E
    Ultima technology will be featured in three posters during the Tuesday poster session at 1:30 pm in Palms Ballroom I:
    101 - Advancing cancer genomics with cost-effective whole genome sequencing: somatic variant calling using the UG 100 platform,​ by Hila Benjamin of Ultima Genomics
    518 - A continued evaluation of the Ultima Genomics UG100 platform: operational advancements and new methods for ancient DNA, single-cell, and methylation applications, by Matthew Coole of the Broad Institute
    592 - Integration of mostly-natural sequencing by synthesis with multiple single cell and spatial assays: 10X Flex, Visium and immune profiling,​ by Gila Yanai of Ultima Genomics
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing a New Era: Part Per Million Detection Accuracy with ppmSeq™️ Technology” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C
    Ultima technology will be featured in three posters during the Wednesday poster session at 4:45 pm in Palms Ballroom I:
    557 - Assessment of Ultima Genomics $100 genome for whole genome sequencing-based cancer diagnostics, by Edwin Cuppen of the Hartwig Medical Foundation
    625 - Scalable Dual Indexed Single Cell WGS on Ultima Genomics, ​ by Andrew Wicks of the New York Genome Center​
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing the Next Wave of Single Cell and Omics at Scale” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

Retrieved on: 
Monday, February 5, 2024

PLEASANTON, Calif., Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

Key Points: 
  • "The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics.
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m.
  • At AGBT, 10x Genomics will unveil new products, features and protocols designed to enable researchers with improved and more cost effective single cell workflows.
  • Throughout AGBT, 10x Genomics will demonstrate the use of its platforms to generate groundbreaking biological insights:
    Sponsor Workshop: Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024).

Element to Present Data on New Products and Multi-Omics Capabilities at AGBT

Retrieved on: 
Monday, February 5, 2024

Never before have so many data points been available to researchers at this cost and speed.

Key Points: 
  • Never before have so many data points been available to researchers at this cost and speed.
  • Cloudbreak UltraQ is the industry's first commercial Q50 kit capable of generating 100-fold higher accuracy than currently available published specifications.
  • Trinity is Element's on-board enrichment solution that simplifies targeted sequencing, to provide users with a new level of convenience, flexibility, and performance.
  • AVITI24 streamlines these studies and data collection to enable rapid recursive learning with broad applications across systems biology.

Kaufman & Broad SA: ANNUAL RESULTS 2023

Retrieved on: 
Monday, February 5, 2024

Main elements of commercial activity (2023 vs. 2022)

Key Points: 
  • Main elements of commercial activity (2023 vs. 2022)
    Main financial items (2023 vs. 2022 unless otherwise specified)
    EBIT margin(c): 7.8 % vs. 7.5%
    Net cash (b) : €180.5M vs. € (67.8 ) M at 30 Nov 2022
    Main development indicators (end of Nov. 2023 vs. end of Nov. 2022)
    Kaufman & Broad SA today announces its 2023 results (from December 1st to November 30th, 2023).
  • Nordine Hachemi, Chairman and Chief Executive Officer of Kaufman & Broad, said:
    “Kaufman & Broad's 2023 results are in line with guidance.
  • In this environment, Kaufman & Broad continued to apply a rigorous policy of rapid adjustment to market conditions.
  • Last September, Fitch confirmed the Investment Grade rating of Kaufman & Broad SA, the only European developer to have this rating.

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Retrieved on: 
Thursday, February 1, 2024

and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the creation of an engineered high-performance transposase enzyme designed to drive superior performance in sequencing applications.

Key Points: 
  • and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the creation of an engineered high-performance transposase enzyme designed to drive superior performance in sequencing applications.
  • The co-development of this new transposase enzyme – called TnX transposase – builds upon a multi-year partnership between the two companies, leveraging Codexis’ strength in enzyme engineering, and seqWell’s expertise in developing tools to improve next-generation sequencing (NGS) performance.
  • Performance data highlighting this enzyme will be presented during the Advances in Genome Biology and Technology (AGBT) General Meeting being held February 5 – 8, 2024 in Orlando, Florida.
  • “Enzymes play a critical role in sequencing workflow chemistries,” said Gavin Rush, Vice President of Research and Development at seqWell.

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

Retrieved on: 
Thursday, February 1, 2024

Under the banner, “Plex YES!”, a theme inspired by customer reactions to the high plex CosMx Human 6K Discovery Panel, NanoString team members and early access researchers will highlight the CosMx SMI’s expanded capabilities with the official product launch at the annual AGBT meeting.

Key Points: 
  • Under the banner, “Plex YES!”, a theme inspired by customer reactions to the high plex CosMx Human 6K Discovery Panel, NanoString team members and early access researchers will highlight the CosMx SMI’s expanded capabilities with the official product launch at the annual AGBT meeting.
  • With the recently announced achievement of the whole transcriptome prototype panel on the CosMx SMI, researchers can now analyze almost 19,000 genes at true single-cell and subcellular resolution.
  • "The CosMx Whole Transcriptome Panel is the ultimate tool for spatial biology; it resulted in new discoveries on my first run.
  • CosMx Human 6K Discovery Panel & CosMx Whole Transcriptome Panel:
    “NanoString Spatial Biology Roadmap: The Holy Grail of Spatial is Here,” presented by Joseph Beechem, Ph.D., Chief Scientific Officer, NanoString, Wednesday, February 7, 3:35-3:50 PM ET.

Zapata AI to Host Virtual Analyst and Investor Webinar on February 8, 2024

Retrieved on: 
Tuesday, January 30, 2024

Zapata Computing, Inc. (“Zapata AI” or the “Company”), the Industrial Generative AI software company developing solutions and applications to solve enterprises’ difficult, industrial-scale problems, and Andretti Acquisition Corp. (“Andretti”) (NYSE: WNNR), a publicly traded special purpose acquisition company, today announced that Zapata AI will host a Virtual Analyst and Investor Webinar on February 8, 2024 from 12:00 to 1:00 p.m.

Key Points: 
  • Zapata Computing, Inc. (“Zapata AI” or the “Company”), the Industrial Generative AI software company developing solutions and applications to solve enterprises’ difficult, industrial-scale problems, and Andretti Acquisition Corp. (“Andretti”) (NYSE: WNNR), a publicly traded special purpose acquisition company, today announced that Zapata AI will host a Virtual Analyst and Investor Webinar on February 8, 2024 from 12:00 to 1:00 p.m.
  • Zapata AI welcomes you to submit questions ahead of time for the Q&A session by emailing [email protected] .
  • As previously announced, Zapata AI entered into a definitive business combination agreement with Andretti Acquisition Corp. (NYSE: WNNR) on September 6, 2023.
  • The registration statement on Form S-4 relating to the business combination was declared effective by the Securities and Exchange Commission (the “SEC”) on January 29, 2024.

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

Retrieved on: 
Tuesday, January 30, 2024

BEIJING, Jan. 30, 2024 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company", together with its subsidiaries, the "Group") (Nasdaq: UXIN), China's leading used car retailer, today announced that it will hold an Extraordinary General Meeting of Shareholders (the "EGM") at 21/F, Donghuang Building, No.

Key Points: 
  • BEIJING, Jan. 30, 2024 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company", together with its subsidiaries, the "Group") (Nasdaq: UXIN), China's leading used car retailer, today announced that it will hold an Extraordinary General Meeting of Shareholders (the "EGM") at 21/F, Donghuang Building, No.
  • 16 Guangshun South Avenue, Chaoyang District, Beijing 100102, People's Republic of China, at 10:00 am (Beijing time) on March 1, 2024.
  • The purpose of the EGM is for the Company's shareholders to consider and, if thought fit, approve the increase in authorized share capital of the Company.
  • Mr. Kun Dai, the Chairman of the Board, has fixed the close of business on February 5, 2024, as the record date (the "Record Date") in order to determine the shareholders entitled to receive notice of the EGM or any adjourned or postponed meeting thereof.